Zentalis Pharmaceuticals Inc (ZNTL) saw an uptrend of 3.25% in the recent trading with $1.59 being its most recent. The current price level -64.19% lower than the highest price of $4.44 marked by the stock while trading over the past 52-weeks, whereas it is 57.43% higher than the lowest price of $1.01 the company dropped to over past 52-weeks. The latest news story on ZNTL appeared in (GlobeNewswire) under the title “Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.11 for the stock.
Zentalis Pharmaceuticals Inc Earnings – What Happened With ZNTL
Coming around sales and income figures on ZNTL Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Zentalis Pharmaceuticals Inc (ZNTL) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 35.69% for net revenue.
ZNTL – Zentalis Pharmaceuticals Inc Stock Earnings Estimates
The perspective of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.87 for stock’s EPS in the current quarter. Zentalis Pharmaceuticals Inc (ZNTL) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 35.69% for net revenue. Company’s EPS for the last quarter was -0.56.
Zentalis Pharmaceuticals Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 72.14 million. ZNTL does have institutional investors; and they hold 69.78% of the stock.
As on 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP was the top most holder in Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) with an ownership of 13.96 million shares of the company or 19.6509 of the stake worth $57.1 million. The filing also reveals FMR LLC as the second largest holder in the company with a control over 12.2139 of the outstanding shares. Its stake is worth $35.49 million for having 8.68 million shares in hand.
EVENTIDE ASSET MANAGEMENT, LLC also came holding a key position in the company during the recent quarter and it now holds 12.0325 of the outstanding shares. With this there are now 147.0 institutions which have possession in ZNTL’s shares.
Key Metrics for ZNTL
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Zentalis Pharmaceuticals Inc has a debt to equity ratio of 0.15.
